{"id":60487,"date":"2024-02-28T06:51:06","date_gmt":"2024-02-28T06:51:06","guid":{"rendered":"https:\/\/medsname.com\/rofaday\/"},"modified":"2026-04-30T10:23:46","modified_gmt":"2026-04-30T10:23:46","slug":"rofaday","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/rofaday\/","title":{"rendered":"Rofaday"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 28px 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 10px 0;font-size:18px;color:#1a1a1a;\">\u26a1 Quick Answer \u2014 What is Rofaday?<\/h3>\n<p><strong>Rofaday<\/strong> bevat <strong>roflumilast 500 mcg<\/strong>, een <strong>oral selective phosphodiesterase-4 (PDE4) inhibitor<\/strong> taken once daily for <strong>severe chronic obstructive pulmonary disease (COPD) with chronic bronchitis phenotype and frequent exacerbations<\/strong>. Roflumilast is anti-inflammatory rather than bronchodilator \u2014 it suppresses neutrophil and macrophage activation in airways, reducing exacerbation frequency by ~17% in landmark trials (M2-124, M2-125, REACT). It is added on top of optimal LAMA + LABA (\u00b1 ICS) in patients with severe disease. Manufactured by <strong>Cipla<\/strong>.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Wat u krijgt bij MedsBase:<\/strong> WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde <a href=\"https:\/\/medsbase.com\/nl\/reviews\/\">klantbeoordelingen<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Elke bestelling is gedekt door onze <a href=\"https:\/\/medsbase.com\/nl\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n<h3>Waarom bestellen bij MedsBase<\/h3>\n<p>Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n<div style=\"background:#f4f8fb;border:1px solid #e0e0e0;padding:12px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;text-align:center;\">\n<strong>\ud83d\udd12 Versleutelde afrekenprocedure<\/strong> \u00b7 <strong>\ud83d\udcb3 Geverifieerde betalingsverwerker<\/strong> \u00b7 <strong>\ud83d\ude9a Wereldwijde verzending<\/strong> \u00b7 <strong>\u2b50 4,9\/5 van 1.400+ klanten<\/strong>\n<\/div>\n<h2>What Is Rofaday?<\/h2>\n<p>Rofaday is an oral PDE4 inhibitor for severe COPD. Roflumilast is the only PDE4 inhibitor licensed for COPD \u2014 sold internationally as Daxas (AstraZeneca) and Daliresp. It is a niche but well-evidenced add-on for the chronic bronchitis phenotype.<\/p>\n<h2>How Does Rofaday Work?<\/h2>\n<p>Phosphodiesterase-4 (PDE4) is the dominant cyclic AMP-degrading enzyme in inflammatory cells (neutrophils, macrophages, eosinophils, T-cells). Inhibiting PDE4 raises cyclic AMP in these cells, suppressing:<\/p>\n<ul>\n<li>Neutrophil chemotaxis and degranulation in airways<\/li>\n<li>Macrophage cytokine release (TNF-\u03b1, IL-8)<\/li>\n<li>Airway smooth-muscle proliferation and fibroblast activation<\/li>\n<li>Mucus hypersecretion and goblet-cell hyperplasia<\/li>\n<\/ul>\n<p>The clinical result is a 15\u201317% reduction in COPD exacerbation rate when added to optimal inhaled therapy.<\/p>\n<h2>Toepassingen en Indicaties<\/h2>\n<ul>\n<li><strong>Severe COPD (FEV1 &lt;50% predicted) with chronic bronchitis<\/strong> and a history of exacerbations, on top of optimal LAMA + LABA (\u00b1 ICS)<\/li>\n<li><strong>Frequent exacerbator phenotype<\/strong> with persistent productive cough<\/li>\n<\/ul>\n<h2>Rofaday Dosage<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Pati\u00ebnt<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Dosering<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Frequentie<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Adults \u2014 start<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><strong>250 mcg<\/strong> for first 4 weeks<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">E\u00e9nmaal daags<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Volwassenen \u2014 onderhoud<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><strong>500 mcg<\/strong><\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Once daily, with or without food<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Leverfunctiestoornis<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid (Child-Pugh B\/C)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Side Effects of Rofaday<\/h2>\n<ul>\n<li><strong>Gewichtsverlies<\/strong> (averages 2\u20133 kg in trials \u2014 monitor; reverse if &gt;5%)<\/li>\n<li>Diarrhoea, nausea (commonest reason for discontinuation; usually settles after first 2\u20134 weeks)<\/li>\n<li>Hoofdpijn<\/li>\n<li>Slapeloosheid, angst<\/li>\n<li>Dyspepsia, abdominal pain<\/li>\n<li>Mood changes \u2014 depression, anxiety; rarely suicidal ideation (warning)<\/li>\n<\/ul>\n<p><strong>Ernstig \u2014 stop en zoek hulp:<\/strong><\/p>\n<ul>\n<li>Severe weight loss (&gt;5% body weight)<\/li>\n<li>New or worsening depression, suicidal thoughts<\/li>\n<li>Severe persistent diarrhoea<\/li>\n<li>Ernstige allergische reactie<\/li>\n<\/ul>\n<h2>Waarschuwingen en voorzorgsmaatregelen<\/h2>\n<ul>\n<li><strong>Mood and behaviour:<\/strong> screen for depression before starting; warn patients\/families to report new mood symptoms.<\/li>\n<li><strong>Weight loss:<\/strong> baseline and 3-monthly weight monitoring; if loss exceeds 5%, review or stop.<\/li>\n<li><strong>Leverfunctiestoornis:<\/strong> avoid in Child-Pugh B and C.<\/li>\n<li><strong>4-week dose titration<\/strong> (250 mcg) reduces GI side effects and diarrhoea \u2014 most patients can then tolerate 500 mcg.<\/li>\n<li><strong>Not a bronchodilator<\/strong> \u2014 does not replace LAMA, LABA, or ICS.<\/li>\n<li><strong>Zwangerschap en borstvoeding:<\/strong> gecontra-indiceerd.<\/li>\n<li><strong>Geneesmiddelinteracties:<\/strong> CYP3A4 inducers (rifampicin) reduce levels \u2014 avoid. Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) raise levels \u2014 caution.<\/li>\n<\/ul>\n<h2>Contra-indicaties<\/h2>\n<ul>\n<li>Hypersensitivity to roflumilast<\/li>\n<li>Moderate-to-severe hepatic impairment (Child-Pugh B\/C)<\/li>\n<li>Zwangerschap<\/li>\n<\/ul>\n<h2>Geneesmiddelinteracties<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Interagerend geneesmiddel<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Effect<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Wat te doen<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">CYP3A4 inducers (rifampicin, phenobarbital, phenytoin, carbamazepine)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduce roflumilast levels by 50%<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Vermijden<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, enoxacin)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Raise roflumilast levels \u2014 increase side effect risk<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Caution; consider lower dose<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Oral contraceptives containing gestodene<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Modest increase in roflumilast levels<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">No dose adjustment usually needed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Opslag<\/h2>\n<ul>\n<li>Bewaren beneden <strong>25\u00b0C<\/strong> op een koele, droge plaats uit direct zonlicht.<\/li>\n<li>Bewaar in de originele verpakking tot gebruik ter bescherming tegen vocht en licht.<\/li>\n<li>Niet gebruiken na de vervaldatum die op de strip staat vermeld.<\/li>\n<li>Buiten bereik van kinderen houden.<\/li>\n<\/ul>\n<h2>Gerelateerde alternatieven op MedsBase<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nl\/asthalin-inhaler\/\"><strong>Asthalin Inhaler \u2014 salbutamol verlichter<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/budecort-inhaler\/\"><strong>Budecort Inhaler \u2014 budesonide ICS-preventer<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/foracort-inhaler\/\"><strong>Foracort Inhaler \u2014 budesonide + formoterol ICS-LABA<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/tiova-inhaler\/\"><strong>Tiova Inhaler \u2014 tiotropium LAMA voor COPD<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/montair\/\"><strong>Montair \u2014 montelukast LTRA-tablet<\/strong><\/a><\/li>\n<\/ul>\n<h2 id=\"faqs\">Veelgestelde vragen<\/h2>\n<h3>When is Rofaday added?<\/h3>\n<p>For severe COPD (FEV1 <50% predicted) with chronic bronchitis phenotype and a history of frequent exacerbations on top of optimal LAMA + LABA (\u00b1 ICS). Not for mild COPD or asthma.<\/p>\n<h3>Why must I start at 250 mcg?<\/h3>\n<p>A 4-week titration at 250 mcg dramatically reduces GI side effects (diarrhoea, nausea) \u2014 most patients can then move to the maintenance 500 mcg without intolerance.<\/p>\n<h3>How much does Rofaday reduce exacerbations?<\/h3>\n<p>About 15\u201317% reduction in moderate-to-severe COPD exacerbations in landmark trials (M2-124, M2-125, REACT). Most benefit seen in the chronic bronchitis with frequent exacerbator phenotype.<\/p>\n<h3>Will Rofaday make me lose weight?<\/h3>\n<p>Yes \u2014 average 2\u20133 kg in trials. Monitor weight at baseline and every 3 months. If loss exceeds 5%, review indication or stop.<\/p>\n<h3>Hoe zit het met stemmingswisselingen?<\/h3>\n<p>Rare but reported. Screen for depression at baseline; counsel patient and family to report new mood symptoms, anxiety, or suicidal thoughts. Stop and review.<\/p>\n<h3>Is Rofaday a bronchodilator?<\/h3>\n<p>No \u2014 it is anti-inflammatory only. Continue your LAMA, LABA, and (where indicated) ICS inhalers.<\/p>\n<h3>Can I take Rofaday during pregnancy?<\/h3>\n<p>Gecontra-indiceerd.<\/p>\n<h3>How does Rofaday compare to triple therapy?<\/h3>\n<p>Triple inhaler (Triohale) and Rofaday tackle COPD exacerbations through different mechanisms (bronchodilation + inflammation suppression vs PDE4-mediated anti-inflammation). Some patients benefit from both.<\/p>\n<h3>What are the most important drug interactions?<\/h3>\n<p>Rifampicin (and other CYP3A4 inducers) reduce Rofaday levels by half \u2014 avoid. Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) raise levels \u2014 caution.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:24px 0;border-radius:4px;font-size:13px;\"><strong>Medische disclaimer:<\/strong> Deze pagina is educatief en vervangt geen professioneel medisch advies. Raadpleeg altijd een gekwalificeerde zorgverlener voordat u een inhaler of respiratoir medicijn start, stopt of wijzigt, vooral als u andere medische aandoeningen heeft, andere voorgeschreven medicijnen gebruikt, zwanger bent of borstvoeding geeft, of ouder bent dan 65.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Gerelateerde alternatieven<\/h3>\n<p>Andere producten in <strong>Chronische aandoeningen<\/strong> die klanten ook bekijken:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nl\/glycomet-gp\/\">Glycomet-GP<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/loratin\/\">Loratin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/lasix\/\">Lasix<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/decdan\/\">Decdan<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/hydrocl\/\">Hydrocl<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Reduces lung inflammation<br \/>\n\u2705 Verbeterde longfunctie<br \/>\n\u2705 Treats chronic bronchitis<br \/>\n\u2705 Decreases COPD exacerbations<br \/>\n\u2705 Enhances breathing capacity<\/p>\n<p>Rofaday contains Roflumilast.<\/p>","protected":false},"featured_media":60488,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3681,3141,3223],"product_tag":[4868,4869],"class_list":{"0":"post-60487","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-asthma-copd-treatment","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","9":"product_tag-rofaday","10":"product_tag-roflumilast","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product\/60487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/comments?post=60487"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media\/60488"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media?parent=60487"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_brand?post=60487"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_cat?post=60487"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_tag?post=60487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}